by combination with MP-470, a multi-targeted TK inhibitor in
prostate and breast cancer," highlighted data indicating that the
combination of MP-470 and erlotinib inhibits the binding of the p85
subunit of PI3K. The poster outlined the enhanced impact of the
combination of MP-470 and erlotinib, compared to either agent alone
in reducing phosphorylation of Akt, ERK1/2, EGFR/HER1, HER2/Neu, and
-- S-110, a DNA methyltransferase inhibitor, demonstrated an improved
in vivo efficacy profile over decitabine (Abstract No. 2613). The
presentation entitled, "Decitabine administered as a Dinucleotide
prodrug increases its in vivo efficacy due to enhanced drug delivery
and stability," highlighted data indicating that S-110 showed robust
anti-tumor activity in prostate and cisplatin-resistant ovarian
carcinoma xenograft models. Additionally, S-110 restored sensitivity
to cisplatin in the ovarian cancer model. Reduced toxicity was
observed along with an increased half-life compared to decitabine.
Conference Call Information
SuperGen will host a conference call to discuss the results of the 2008 first quarter financial results today at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the conference call is accessible via the investor relations section of the Company's web site at http://ir.supergen.com. A webcast replay of the conference call will be available for 90 days.
Based in Dublin, California, SuperGen, Inc. is a pharmaceutical company
dedicated to the discovery, rapid development and commercialization of
therapies for solid tumors and hematological malignancies. SuperGen is
developing a number of therapeutic anticancer products focused
|SOURCE SuperGen Inc.|
Copyright©2008 PR Newswire.
All rights reserved